01:15 on September 28, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock fluctuated, and the stock price soared by 5.03%. As of press time, the stock was trading at US $0.547 per share, with a turnover of 4007 shares, a turnover rate of 0.01% and an amplitude of 0.005%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.010, gross profit of $419.00, and price-to-earnings ratio of-66.73 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP's shares are located on the US OTC market, the overall decline is 1.03 per cent. Among its related stocks, Aurora Mobile Limited marijuana,Radius Health Inc、Lannett Co IncThe increase is relatively large.Flora Growth Corp.、Denawi Pharmaceuticals、Cardiol Therapeutics IncRelatively active, with turnover rates of 8.38%, 4.21% and 3.30% respectively. The related stocks with larger amplitudes are Flora Growth Corp.,Jupiter Wellness Inc C/Wts 170.06 Universe 2025 (To Pur Com)、Alpha Teknova, Inc.The amplitudes were 21.45%, 19.24% and 15.88%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )